Dr. Richard Gliklich, MD is the CEO of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles.

Dr. Gliklich is well known in the areas of registries, outcomes and analytics. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook "Registries for Evaluating Patient Outcomes: A User's Guide” and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement. He has led several key national and international efforts focused on evaluating the safety, effectiveness, value and quality of healthcare. Dr. Gliklich also holds several patents for both health outcomes systems and medical devices.

Dr. Gliklich is a graduate of Yale University and Harvard Medical School and a former Charles A. Dana Scholar at the University of Pennsylvania. He is also a surgeon and the Leffenfeld Professor at Harvard Medical School.

Shawn is a seasoned commercial executive with nearly 30 years of leadership and life sciences expertise. His journey has been one of global transformational leadership; innovating SaaS, DaaS, and service go-to-market strategies; creating and empowering high-performance cultures; and consistently delivering double-digit growth. Shawn’s leadership spans the full lifecycle of product development and commercialization for Fortune 100 life science companies to agile software and service startups.

A distinguished graduate of The Citadel, Shawn secured a Bachelor of Science in Electrical Engineering and Computer Science. His time there was further marked by his induction into the Tau Beta Pi Engineering Honor Society and the bestowed honor of US Army Distinguished Military Graduate. Beyond academia, Shawn is also a certified Lean Six Sigma Black Belt, showcasing his commitment to excellence and continuous improvement.

At OM1, Shawn plays a crucial role as the Chief Commercial Officer, steering the commercial strategy, sales, marketing, operations, strategic alliances, pricing, and contracting. His leadership is a catalyst for our customer-centric commercial models, consecutive years of impressive growth, and a pioneering go-to-market strategy.

Before OM1, Shawn's transformative touch was evident at Certara. He was the Global Commercial Head for Certara’s RWE, Access, MedAffairs, and Regulatory business unit. Prior to that, he served as the General Manager for Certara’s Evidence, Access, and MedAffairs software portfolio. There, he championed and scaled customer-centric commercial frameworks, yielded successive years of robust growth, and unveiled a fresh go-to-market approach that saw the expansion and launch of new service lines and software products.

Earlier in his career, at industry titans like IQVIA, Awen, Philips, Sirona, and Eli-Lilly, Shawn held successive top global leadership roles across all commercial functions and subject matter expert consultative roles providing RWE, HEOR, Market Access, and Medical Affairs solutions. His contributions were pivotal in ushering groundbreaking product launches across specialties in Rare Disease, Oncology, Neuroscience, Cardiology, and Diabetes. Not to be overshadowed, Shawn's service as a highly decorated US Army Intelligence officer for nearly a decade speaks volumes of his dedication and leadership prowess. Exiting the army with the honorable title of Captain, he smoothly transitioned his leadership skills to the life sciences technology sector.

Shawn is committed to enabling and accelerating innovation to offer hope to patients with difficult-to-treat diseases. He has served in advisory roles for the Cancer Research Institute and the National Pediatric Cancer Foundation offering advocacy solutions in collaboration with industry.

Shawn’s guiding philosophy is, “An organization’s success rests on a leader’s ability to create an authentic harmony between a compelling vision, an empowering culture, and a well laid out strategic course. Most importantly, an ensemble of aligned decisive leaders, embracing failures as stepping-stones, can propel a company into a whirlwind of bold innovation. It must be a genuine state of being.”

Dennis Reilly is the Chief Financial Officer at OM1, Inc. Prior to joining OM1, he was the VP, Finance at Aptus Health, a global digital health company acquired by WebMD. Prior to Aptus, Dennis worked at several venture-backed healthcare technology companies.

Dennis began his career at Arthur Andersen as a CPA and corporate auditor. He received his BS from Merrimack College.

Madelyn is the Chief People Officer at OM1, Inc., where she leads the organization’s people
strategy, helping OM1 continue to build a community of diverse and high-performing talent and cultivate an inclusive, empowering and connected employee experience.

Prior to OM1, Madelyn was the Vice President of People at Kyruus, Inc. where she led the
People team’s efforts across Talent Acquisition, Talent Development, Employee Relations, Total Rewards, and Diversity, Equity, Inclusion & Belonging. Prior to Kyruus, Madelyn served as Senior Director, HR Business Partner and Head of Talent Development at Ascend Learning, an education technology company supporting students and educators in areas of Healthcare, Fitness & Wellness, and Safety & Security.

Before launching her career in human resources, Madelyn spent several years as an external consultant in areas of Talent Management / Development and Organizational Change, serving both multinational corporations as well as small businesses and non-profit organizations.

Madelyn received a BA in Psychology from Connecticut College and an MA in Social and
Organizational Psychology from Columbia University.

Dan Levy is the Chief Data Officer at OM1, Inc. In his role, Dan is responsible for developing and managing the partner ecosystem, with a focus on creating data solutions that generate value to both OM1 customers and partners.

For the prior 4 years, Dan was Chief Technology Officer at Amazing Charts, an ambulatory electronic medical record and health IT company. Dan led the software engineering, quality assurance, cloud operations, and data & analytics functions, and helped lead the company through an acquisition to Harris Healthcare. For the 8 years prior, Dan served as Vice President of Engineering and later as Chief Technology Officer at Outcome Sciences, a division of Quintiles, focusing on real-world and late phase research.  Prior to that, Dan held a number of technical leadership roles in both public and private, venture backed companies.

Dan received a BA in General Science from Brandeis University and an MS in Software Engineering from Boston University.

Eric Schrock is the Chief Technology Officer at OM1, Inc. In this role, he is responsible for the Product Engineering, Data Engineering, IT, and Security teams that develop and operate OM1's technology platform and products.

Prior to OM1, Eric was the Chief Technology Officer and Co-CEO at Jvion, a clinical AI company that uses prescriptive intelligence to improve patient outcomes. There, he ran the engineering, data science, professional services, and customer success teams responsible for product development and delivery. Prior to Jvion, Eric was VP of Engineering and CTO at Delphix, a data virtualization company that simplifies the delivery of secure production data to enterprise teams. Early in his career, Eric developed complex enterprise software systems including operating systems, filesystems, and hardware storage appliances.

Costas Boussios, PhD is the Chief Data Scientist at OM1, where he leads research and development of OM1's AI solutions. Prior to OM1, Dr. Boussios was the Chief Data Scientist at Mitra Capital LLC, the top performing equity market neutral fund of 2015. He has also led Data Science at Cignifi Inc, where he developed credit scoring solutions using mobile telephony data for millions of unbanked consumers in developing countries, and at Zakipoint Health LLC, where he developed patent-pending technology in optimization of health goal program engagement and adherence. He has also held the position of Director of Analytics at D&B working on commercial credit and insolvency risk scoring. Dr. Boussios holds a PhD from Mechanical Engineering at MIT with specialization in Machine Learning and Feedback Control Systems.

Dr. Carl Marci is the Chief Clinical Officer and Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. Previously, he was Chief Psychiatrist and Chief Medical Officer at several venture backed health and technology companies. He is a 2023  PharmaVoice 100 Honoree.

Dr. Marci is board certified and is part-time staff at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School, he completed two NIH Fellowships in neuroscience and has published numerous articles in peer-review science journals. He holds seven patents and is author of a forthcoming book on the impact of technology on the brain.

Dr. Marci is a graduate of Columbia University and Oxford University where he was a Rhodes Scholar. He then went to Harvard Medical School and graduated with honors; he is also the former Director of Social Neuroscience at Massachusetts General Hospital.

Sonja Wustrack, MPH is the Managing Director of Integrated Evidence Generation at OM1, responsible for the design and execution of OM1 retrospective and prospective registries using networks and platforms. Sonja has over 20 years experience working in the Pharma/CRO space in various positions across Operations, Sales, Account Management and Strategy. Prior to OM1, Sonja was at Verana Health where she led the Commercial Operations teams. Sonja spent a number of years in the CRO space, most recently at IQVIA, where she held a number of positions from Account Management, Demand Generation, Clinical Delivery and RWE offering development. Sonja has a MPH in Epidemiology from Tulane University School of Public Health and a BA in Biology from Vassar College.

Kathryn is the Vice President of Real World Evidence at OM1. Previously, she was the Senior Director of Epidemiology and Outcomes Research at Outcome (now part of the late phase division of IQVIA).

Prior to Outcome, she served as lead for safety and risk management for products from clinical development through to post-marketing, with particular expertise in rare diseases, biologics and gene therapy applications at Genzyme. She has also held research positions at the NIH, Columbia and Harvard.

Kathryn is a graduate of Dartmouth College and the Harvard T.H. Chan School of Public Health.

Joseph Zabinski, PhD, MEM is VP, Head of Commercial Strategy & AI at OM1. He oversees design, implementation, and evolution of OM1's commercial strategy, including prioritization, go-to-market planning, and alignment with emergent market needs. Dr. Zabinski also serves as subject matter expert and thought leader for OM1's AI work, including applications of the PhenOM digital phenotyping platform with life science and healthcare provider partners.Prior to joining OM1, Dr. Zabinski was a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Co. He specialized in advising life science and healthcare clients on using AI and advanced analytics, including identification of unmet medical needs, portfolio optimization, and AI strategy. His academic research focused on applications of Bayesian network modeling methods to predicting and stratifying environmental human health risk.Dr. Zabinski holds a master’s degree in engineering management from Dartmouth College, and a doctorate with a focus in health analytics from the School of Public Health at the University of North Carolina, Chapel Hill.

Joe is a 2023 Healthcare Innovation 40 Under 40 Winner.

Tom Engel is the Vice President of Business Development for OM1, Inc. Previously, Tom led the US Sales Team for QuintilesIMS Real World Evidence following the merger of Quintiles and IMS Health. Prior to the merger, Tom led the North America Sales Team for Real World and Late Phase Research at Quintiles (NYSE: Q), the world's largest Clinical Research Organization (CRO). In 2004, Tom joined Rich Gliklich at Outcome Sciences, Inc. (Outcome) where he focused on sales and market development through the 2011 acquisition of Outcome by Quintiles.

In 1998, Tom joined Phase Forward (later acquired by Oracle) as the first Product Manager for InForm, the market-leading electronic data capture system for clinical development. He joined IntraLinks, Inc. in 2002 as Vice President of Strategic Business Development tasked to develop new sales channels for IntraLinks’ clinical products.

Tom received his Bachelor of Arts degree from Boston College in Mathematics a very long time ago. When not at home with his family, Tom can be found walking in the woods or on the nearest mountain.

As the VP of Marketing and Communications at OM1, Inc, Renee Hurley oversees strategy and implementation of the marketing, communications, and thought-leadership programs. Prior to joining OM1, Renee led the global marketing strategies, initiatives and teams for Quintiles Integrated Healthcare Services (IHS), which included Real-World & Late Phase Research, Commercial, Health Engagement & Communications, Advisory Services, and Payer & Provider business units.

In previous roles, Renee oversaw real-world research and provider marketing, communications and thought-leadership for Outcome Sciences Inc., worked in a variety of marketing roles for primary care and specialty conferences at MC Communications, and was a media researcher at MediaMap. She is an alumni of Boston University and enjoys exploring the world and hiking with her family.